Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Bluejay Diagnostics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/16/2023 8-K Quarterly results
Docs: "Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Bluejay Diagnostics Regains Compliance with"
07/21/2023 8-K Quarterly results
06/05/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/19/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy"
05/18/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "Bluejay Diagnostics Reports First Quarter 2023 Financial Results"
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/27/2023 8-K Quarterly results
03/20/2023 10-K Annual Report for the period ended December 31, 2022
03/20/2023 8-K Quarterly results
01/27/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "First Amendment to Employment Agreement, entered into and effective as of January 27, 2023, between Bluejay Diagnostics, Inc. and Neil Dey"
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results Acton, Massachusetts, October 25, 2022 – Bluejay Diagnostics, Inc. , a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the quarter and nine months ended September 30, 2022. “The last quarter focused on increasing awareness of Bluejay’ s Symphony IL-6 test by directly engaging the medical community to build a network of champions that will direct product development and drive initial commercialization,” said Neil Dey, CEO. “In August, Bluejay held a KOL event with clinicians in emergency and critical care who shared their perspectives on Symphony’ s pot..."
10/28/2022 8-K Quarterly results
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/26/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
05/12/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/09/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/20/2022 8-K Quarterly results
Docs: "Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results"
04/19/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
04/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement between Bluejay Diagnostics, Inc. and Gordon Kinder"
03/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement between Bluejay Diagnostics, Inc. and Kenneth Fisher",
"BLUEJAY DIAGNOSTICS, INC. PRESS RELEASE DATED MARCH 23, 2022"
03/10/2022 8-K Quarterly results
03/10/2022 10-K Annual Report for the period ended December 31, 2021
01/31/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA Acton, Massachusetts, January 31, 2022 – Bluejay Diagnostics, Inc. a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that it has filed a Pre-Submission package for the Symphony IL-6 Test with the U.S. Food and Drug Administration . The purpose of this filing is to request feedback from the agency prior to submitting a medical device marketing application. The pre-submission package will allow the FDA to review and comment on the Company’ s plans for clinical trials and analytical testing. Neil Dey, Bluejay’ s Chief Executive Officer commented “I am ve..."
01/04/2022 SC 13G/A SABBY MANAGEMENT, LLC reports a 5% stake in Bluejay Diagnostics, Inc.
12/22/2021 SC 13D Wurth Douglas Clark reports a 27.3% stake in Bluejay Diagnostics, Inc.
12/22/2021 SC 13D Dey Indranil reports a 35.8% stake in Bluejay Diagnostics, Inc.
12/16/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy